Skip to content

Frequently Asked Questions

You aren’t the first to ask.

There are always questions when starting a new program or therapy, so we make it easy to help get the answers you need. United Therapeutics Cares™ is available to assist, or you can browse our frequently asked questions here.

Enrollment

United Therapeutics Cares provides ongoing, one-on-one education and support for adults diagnosed with PAH or PH-ILD who have been prescribed a United Therapeutics medication. Your dedicated Patient Navigator will personalize support and answer questions about what to expect as you begin treatment, insurance coverage, out-of-pocket cost assistance, and prescription fulfillment.

Even if you are not enrolled in United Therapeutics Cares, you can still benefit from reaching out to our team with any questions regarding the safe and effective use of your United Therapeutics therapy.

United Therapeutics Cares representatives are available Monday through Friday, from 8:30 am to 7:00 pm ET. You can reach them at 1-844-864-8437.

Our mailing address is P.O. Box 12015, Research Triangle Park, NC 27709.

While the names ASSIST and Archways will no longer exist, the same services are available with our new United Therapeutics Cares program. Additional education and support services will also be available to you to help streamline your needs and get you started on United Therapeutics therapy.

Any person who is prescribed Orenitram®, Remodulin®, ADCIRCA®, TYVASO®, or TYVASO DPI® , or their caregiver, that has provided the required consent and authorization can enroll.

Enrolling in United Therapeutics Cares is easy. You will work with your healthcare provider to complete the patient enrollment form. The form includes sections for your signature and your healthcare provider’s signature. Once your enrollment form is received, a Patient Navigator will call you to discuss next steps. For questions, call 1-844-864-8437. Our team is available Monday through Friday, 8:30 am to 7:00 pm ET.

Consent forms can be found on our website at the link below or by calling United Therapeutics Cares.

See consent form

Once your enrollment is received at United Therapeutics Cares, your Patient Navigator will reach out to introduce themselves and provide you with helpful program information. Keep an eye out for a phone call from our team.

Enrollment in United Therapeutics Cares is optional and participation is not required to start a United Therapeutics medication. If you wish to withdraw your enrollment and consent you can call United Therapeutics Cares at 1-844-864-8437 or email us at opt-out@UnitedTherapeuticsCares.com.

Education & Expectations

In order for United Therapeutics Cares to disclose any medical information related to a patient, we must have the appropriate consent on file. Until we have obtained your written consent to speak to a caregiver, we are unable to share any of your information. Alternatively if you (or your legal representative) provide verbal consent over a live phone call attended by the caregiver, the requested information can be shared with your caregiver during the call.

Yes, patients and caregivers can opt in to receive outreach from the program via email, phone calls, and/or text messages based on your preference. Talk to your Patient Navigator about establishing your preferred communication methods. You can change your communication preferences at any time.

To opt out of email communications, you can email us at opt-out@UnitedTherapeuticsCares.com.

To unsubscribe from text messages you can either text STOP in the text thread from United Therapeutics Cares or give us a call at 1-844-864-8437.

The Patient Navigator is the primary point of contact for those enrolled in United Therapeutics Cares. Patient Navigators will personalize support and answer questions about what to expect as you begin a United Therapeutics treatment and navigate insurance coverage, out-of-pocket cost assistance, prescription fulfillment, and education.

You can call United Therapeutics Cares at 1-844-864-8437. You can also request a call back on our Contact page.

Get to know our full United Therapeutics Cares team on the Your Team page.

Once enrolled, a Patient Navigator will give you a call to introduce themselves, walk you through the details of the United Therapeutics Cares program and answer questions you may have about starting a United Therapeutics treatment.

Then, United Therapeutics Cares will get the ball rolling to review your insurance coverage and inform you of potential cost-savings options that may help you afford your treatment. We will connect you to your Specialty Pharmacy to discuss prescription fulfillment.

We have an experienced team of Patient Education Specialists (PES) who provide personalized education to our patients. The PES team can assist you with questions about your United Therapeutics medication, titration, pump devices, and other common therapy topics.

United Therapeutics and United Therapeutics Cares do not provide medical advice, and all treatment-specific questions or concerns should be discussed with your healthcare provider. Additionally, your Specialty Pharmacy (CVS or Accredo) offers in-home nurse product training by a team of expertly trained nurses. These nurses can provide hands-on administration training as you start your medication.

Insurance & Coverage

Our Access and Affordability Specialists coordinate with you, your providers, and the Specialty Pharmacy to help understand your insurance coverage and the potential out of pocket costs associated with your medication. Financial assistance options may be available based on eligibility.

United Therapeutics Cares offers a Patient Assistance Program for uninsured and underinsured people who meet eligibility requirements.

United Therapeutics Cares can help navigate the benefits investigation process and outline requirements for prior authorizations, denials, and appeals as needed. Based on eligibility, we can also share options that may be available like United Therapeutics’ co-pay assistance and Patient Assistance Program.

A prior authorization is when your health insurer must approve a medical procedure, treatment, or prescription before it is provided. It is common for insurance providers to require a prior authorization to be submitted for United Therapeutics products. Your healthcare provider will complete the prior authorization request and submit it to your insurance provider.

To be eligible to enroll in the United Therapeutics Cares Patient Assistance Program, you must be a US resident, prescribed a United Therapeutics therapy, and a patient enrollment form must be completed by your healthcare provider and received by the program. Consent must be provided by you to conduct a benefits investigation and validate household income via a third-party income verification service. Once completed and if eligible, an Access and Affordability Specialist will notify you of coverage and will work with the Specialty Pharmacy to coordinate delivery.

If you have a commercial or private insurance plan, United Therapeutics Cares offers a co-pay card to help eligible patients cover some of their out-of-pocket expenses. Our co-pay assistance program will pay the difference of your prescription cost up to the annual maximum benefit.

You must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible. Those under 18 years of age are not eligible to register for the program. Visit unitedtherapeuticscarescopay.com to determine if you qualify.

If your insurance changes, be sure to let your Patient Navigator know as soon as possible. New insurance may affect your coverage, but United Therapeutics Cares can help you understand your new coverage and explore options that may be available to you based on eligibility.

Reach out to your Patient Navigator directly or through our Contact page.

Cost & Savings

In addition to helping navigate your insurance coverage, we can educate you on financial aid resources that may help you pay for out-of-pocket costs. If eligible, options could include co-pay assistance and the United Therapeutics Patient Assistance Program.

Depending on eligibility, co-pay assistance and the United Therapeutics Cares Patient Assistance Program can help those eligible pay as little as $0 per month for your prescription.

Prescription & Coordination

Yes, your Patient Navigator will monitor your prescription status from prior authorization to shipment while also being available to answer any questions. You also can contact your pharmacy directly for more information.

No, United Therapeutics medication will be sent to your home or the office of your healthcare provider from a Specialty Pharmacy, either CVS Specialty or Accredo.

A Specialty Pharmacy is a pharmacy that provides medications for chronic, serious, or rare conditions that may require special care. These medications often require prior authorizations or need to be handled and taken in specific ways, like injections or specialized pills. United Therapeutics Cares works with two Specialty Pharmacies, CVS Specialty and Accredo. They partner with our Patient Navigators to help coordinate the delivery of medication and offer ongoing assistance.

Any decision to switch therapy must be made between you and your doctor.

Treatment Support

There are two ways to reach out to your United Therapeutics Cares support team. You can call us directly at 1-844-864-8437 or by requesting a call on our Contact page. Our team is available Monday through Friday, 8:30 am to 7 pm ET.

There’s no shortage of educational resources your support team can connect you to, from treatment-specific downloads that shed light on your medication to disease education.

Explore our Resource Library for a list of materials, or visit our Community page to discover additional third-party resources.

United Therapeutics Cares has information on a wide network of pulmonary hypertension organizations with support groups for adults living with PAH and PH-ILD. Visit the Community page of our website to begin exploring what this support can look like.

Consult your healthcare provider with all of your medical questions. United Therapeutics Cares does not make medical recommendations or provide medical advice.

Medication disposal information can be found at myoldmeds.com or fda.gov.

Follow the instructions provided with your medication, including prescribing information and securely store and dispose of unwanted, unused, or expired medicines from households.

Looking for a resource?

Explore our Resource Library
A woman looks out a sunny window

Need one-on-one support?

Reach out
Expand

SELECT IMPORTANT SAFETY INFORMATION

Orenitram

  • Do not take Orenitram if you have severe liver problems.

Remodulin

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.

ADCIRCA

  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5’s can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA.

TYVASO and TYVASO DPI

  • Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you have low blood pressure or have had bleeding problems.

Please see below for Indication, additional Important Safety Information, and links to the Full Prescribing Information for Orenitram, Remodulin, ADCIRCA TYVASO, and TYVASO DPI.

SELECT IMPORTANT SAFETY INFORMATION

Orenitram

  • Do not take Orenitram if you have severe liver problems.

Remodulin

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.

ADCIRCA

  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i). PDE-5’s can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA.

TYVASO and TYVASO DPI

  • Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you have low blood pressure or have had bleeding problems.

Treatment options for adult patients with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO and TYVASO DPI are also indicated for adult patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3).

Please see below for Indication, additional Important Safety Information, and links to the Full Prescribing Information for Orenitram, Remodulin, ADCIRCA, TYVASO, and TYVASO DPI.

What is Orenitram?

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram can help slow down the progression of your disease and improve your ability to exercise. It is not known if Orenitram is safe and effective in children.

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

Who should not take Orenitram?

Do not take Orenitram if you have severe liver problems.

What should I tell my healthcare provider before taking Orenitram?

Tell your healthcare provider:

  • If you have liver problems or diverticulosis.
  • If you are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Orenitram.
  • About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains treprostinil, such as Remodulin® or Tyvaso®.

How should I take Orenitram?

  • Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.
  • Orenitram is usually taken 3 times a day (about every 8 hours) or 2 times a day (about every 12 hours). Your healthcare provider will tell you how often you should take Orenitram. If you have side effects, your healthcare provider may tell you to change your dose or when you take Orenitram. Take Orenitram with food.
  • Swallow Orenitram tablets whole. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects.
  • If you miss your dose of Orenitram, take the missed dose as soon as possible with food.
  • If you miss 2 or more doses of Orenitram, call your healthcare provider to see if you need to change your dose.
  • If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.
  • You may see the tablet shell in your stools (bowel movements). This is usually normal. The tablet shell is not digested. If you have diverticulosis, the tablet shell may get stuck in a blind pouch or diverticulum in your intestine.

What are the possible side effects of Orenitram?

Orenitram can cause serious side effects, including worsening of PAH symptoms.

  • Stopping Orenitram suddenly may cause worsening of your PAH symptoms. Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.
  • The most common side effects of Orenitram include headache, diarrhea, nausea, vomiting, flushing, and pain in arms, legs, and jaw. These are not all of the possible side effects of Orenitram. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
  • Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about Orenitram, talk with your healthcare provider. Please see Full Prescribing Information and Patient Information at www.orenitram.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

OREISIconOCT19

What is Remodulin?

Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin issafe and effective in children.

In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.

IMPORTANT SAFETY INFORMATION FOR REMODULIN

Before you take Remodulin, tell your healthcare provider if you:

  • Have other medical conditions or take other medicines that may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness.
  • Have liver or kidney problems. Your Remodulin dose may need to be adjusted if you have liver problems.
  • Have low blood pressure or bleeding problems.
  • Are taking gemfibrozil (for high cholesterol), rifampin (for infection) or other drugs that affect liver enzymes. Your doctor may need to adjust your Remodulin dosage.
  • Are pregnant, breastfeeding, or planning to become pregnant. It is not known if Remodulin will harm your unborn baby or if Remodulin passes into your breast milk.

What are the serious side effects of Remodulin?

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • Worsening of PAH symptoms. Do not stop taking or greatly reduce your Remodulin dose without consulting your doctor.
  • Low blood pressure (symptomatic hypotension). If you have low blood pressure or are taking drugs that lower your blood pressure, the risk of low blood pressure is increased.
  • Bleeding problems. Remodulin may increase the risk of bleeding in people who take blood thinners (anticoagulants).

What are the possible side effects of Remodulin?

  • In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin.
  • IV infusion of Remodulin delivered through an external pump has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain.
  • The most common side effects seen with either SC or IV Remodulin were headache, diarrhea, nausea, rash, jaw pain, widening of the blood vessels (vasodilatation), and swelling from fluid retention (edema). These are not all the possible side effects of Remodulin. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about Remodulin, talk with your healthcare provider. Please see Full Prescribing Information at www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

REMISIconMAY2021

Important Safety Considerations for ADCIRCA® (tadalafil)

  • You should discuss all of your medical conditions and all medications with your healthcare provider before starting ADCIRCA
  • Do not take ADCIRCA if you take any medications that contain nitrates (often used for chest pain) or guanylate cyclase stimulators, as the combination could cause a sudden, unsafe drop in blood pressure
  • Do not take ADCIRCA if you are allergic to tadalafil or any other ingredient in ADCIRCA
  • ADCIRCA is a type of medication called a phosphodiesterase 5 inhibitor (PDE-5i) that can cause blood vessels to widen, which may result in a decrease in blood pressure. If you have heart-disease or any problems with low blood pressure, tell your healthcare provider before taking ADCIRCA, as these conditions may be affected by the action of ADCIRCA
  • Talk with your healthcare provider if you are pregnant or planning to become pregnant or if you are breastfeeding or plan to breast feed.
  • If you have ever had blockage in the veins of your lungs, known as pulmonary veno-occlusive disease (PVOD), ADCIRCA is not recommended for you
  • Taking ADCIRCA with alcohol, or blood pressure medications, such as alpha-blockers, may lower blood pressure and cause hypotension (light-headedness or fainting)
  • Do not take ADCIRCA if you are taking rifampin (an antibiotic for certain bacterial infections), or antifungal medications, such as ketoconazole and itraconazole. If you require treatment with both ADCIRCA and ritonavir (Norvir®) at the same time, your dose of ADCIRCA will need to be adjusted. Inform your healthcare provider if you have kidney or liver problems before taking ADCIRCA
  • ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED, impotence) and the signs and symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). If you are taking ADCIRCA, do not take Cialis or other PDE-5is
  • In rare cases, patients reported side effects such as decreased eyesight or loss of vision in one or both eyes (NAION), or sudden decrease or loss of hearing, sometimes with ringing in the ears and dizziness. If you experience any of these side effects after taking ADCIRCA, seek medical attention right away
  • In rare cases, men taking PDE-5is (including tadalafil) for erectile dysfunction reported side effects such as an erection lasting more than four hours. If you experience a prolonged erection, seek medical attention right away
  • The most common side effects of ADCIRCA are headache, muscle pain, getting red or hot in the face (flushing), nausea, pain in the arms, legs or back, upset stomach, stuffy or congested nose

ADC.ISI.CON.SEP2020

For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

IMPORTANT SAFETY INFORMATION FOR TYVASO and TYVASO DPI

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI™ Inhalation Powder, and additional information at www.TYVASO.com or call 1-877-UNITHER (1-877-864-8437).

TYVISIconMAY2022